Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

In today’s episode, we spoke with Nicholas Short, MD. Dr Short is an associate professor in the Department of Leukemia of the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

In our exclusive interview, Dr Short discussed evolving factors at play for the treatment of patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). He also noted how the TKI ponatinib (Iclusig) stacks up against other TKIs for Ph-positive ALL, in addition to evolving approaches that incorporate treatments like blinatumomab (Blincyto).